Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome

超越阿扎胞苷：研究治疗骨髓增生异常综合征的新治疗靶点

• 批准号: nhmrc : GNT1163815
• 金额: $ 58.89万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/azacitidine-investigating-new-myelodysplastic-syndrome/1379320
• 关键词: Beyond; Azacitidine; Investigating; new; therapeutic

The drug Azacitidine (AZA) is the best available treatment for patients with the blood cancer Myelodysplastic Syndrome (MDS). However, more than half of the treated patients will never respond to treatment. Furthermore, a significant fraction of the patients will eventually relapse, highlighting a need to develop more effective and durable therapies. Here, we will investigate molecular mechanisms within MDS cells affected by AZA, as a means to develop new treatment options for MDS.

阿扎胞苷（Azacitidine，AZA）是治疗骨髓增生异常综合征（MDS）的最佳药物。然而，超过一半的患者将永远不会对治疗作出反应。此外，很大一部分患者最终会复发，这突出表明需要开发更有效和持久的治疗方法。在这里，我们将研究AZA影响MDS细胞的分子机制，作为开发MDS新治疗方案的一种手段。